Molecular Cancer Therapeutics · 2008 · 27 citations · 36 references
MedicineOncologyPharmacologyApoptosisGlial BiologyNeuro-oncologyAstrocyte BiologyBrain TumorsGlial Cell BiologyGlial Cell Molecular BiologyGlial PathologyGlioblastomaArachidonic Acid BiosynthesisArachidonic Acid MetabolitesArachidonic Acid SignalingAstrocytoma PathologyCyclooxygenase-2 PathwayGlioblastoma Tumor BiologyMalignant ProgressionProstaglandin D2 Biosynthesis
Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D(2) (PGD(2)) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGD(2), to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGD(2) substitution also enhanced the efficacy of cyclo-oxygenase-2 inhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.
36
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D. Craig Allred, Jennet Harvey, Melora D. Berardo et al. · PubMed · 1998 · 2.2K citations
Medicine, Cancer Biology, Oncology +16
Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays.
Huatao Huang, Stefano Colella, Michael Kurrer et al. · PubMed · 2000 · 171 citations
Chenguang Wang, Maofu Fu, Mark D’Amico et al. · Molecular and Cellular Biology · 2001 · 162 citations · Full text